Director adds 2,269 Processa (PCSA) shares at $2.535 each

Rhea-AI Filing Summary

Processa Pharmaceuticals director Baluch Khoso bought shares of the company in the open market. On this transaction date, he purchased 2,269 shares of Common Stock at an average price of $2.535 per share in an open-market purchase. Following this trade, he directly owns 2,325 Processa Pharmaceuticals common shares.

Insider Trade Summary

Net Buyer: 2,269 shares ($5,752)

Net Buy 1 txn

Insider Baluch Khoso

Role Director

Bought 2,269 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,269	$2.535	$6K

Holdings After Transaction: Common Stock — 2,325 shares (Direct)

Footnotes (1)

Key Figures

Shares purchased: 2,269 shares Purchase price: $2.535 per share Shares owned after trade: 2,325 shares +1 more

4 metrics

Shares purchased 2,269 shares Open-market purchase of Common Stock

Purchase price $2.535 per share Price paid for Common Stock

Shares owned after trade 2,325 shares Direct holdings following transaction

Net share change 2,269 shares Net buy per transactionSummary

Key Terms

open-market purchase, Common Stock, transaction code, non-derivative

4 terms

open-market purchase financial

"transaction_action is described as "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"security_title is listed as "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code financial

"the filing uses transaction_code "P" for the trade"

non-derivative financial

"transaction_type is classified as "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baluch Khoso

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		2,269	A	$2.535	2,325	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Khoso Baluch by John J. Wolfel, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA director Baluch Khoso report?

Baluch Khoso reported an open-market purchase of Processa Pharmaceuticals shares. He bought 2,269 shares of Common Stock in a single transaction, as disclosed in a Form 4 insider filing, increasing his direct ownership in PCSA.

How many Processa Pharmaceuticals (PCSA) shares did the director buy?

The director bought 2,269 PCSA common shares. This open-market purchase increased his direct holdings to 2,325 shares after the transaction, according to the Form 4 insider trading disclosure.

What price did the PCSA director pay per share in the Form 4 transaction?

He paid an average price of $2.535 per PCSA share. The Form 4 states that 2,269 shares of Processa Pharmaceuticals Common Stock were acquired in an open-market purchase at this per-share price.

What are Baluch Khoso’s PCSA holdings after this insider trade?

After the reported transaction, he holds 2,325 PCSA shares directly. The Form 4 shows this total share count following the open-market purchase of 2,269 shares of Processa Pharmaceuticals Common Stock.

Was the PCSA insider transaction a purchase or a sale?

The transaction was a purchase of PCSA shares. The Form 4 uses transaction code “P” and describes it as an open-market purchase of Common Stock by director Baluch Khoso, not a sale or disposition.